ArticleMovement disorders clinical practice2026
Basal Forebrain Volume Predicts Disease Conversion in Prodromal Synucleinopathy.
Article in Movement disorders clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Data-driven trajectories of atrophy explain clinical heterogeneity across Lewy body diseases.medRxiv : the preprint server for health sciences · 2026Article
- Pedunculopontine-thalamic cholinergic projections in rapid eye movement sleep behaviour disorder.NPJ Parkinson's disease · 2026Article
- Functional Magnetic Resonance Imaging (fMRI) Signatures of Progression and Phenoconversion in Prodromal Synucleinopathies.Movement disorders : official journal of the Movement Disorder Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundIsolated rapid eye movement sleep behavior disorder (iRBD) is a prodromal stage of Parkinson's disease (PD) and dementia with Lewy bodies (DLB). The basal forebrain (BF), a key cholinergic structure, is a site of known pathology in later stages of Lewy body disorders. Although bilateral BF atrophy has been linked to cognitive decline in iRBD, its potential role in predicting phenoconversion to PD and DLB remains unclear.
objectivesThe aims were to examine BF gray matter volume differences between iRBD patients and healthy controls, and evaluate their utility as predictors of phenoconversion to PD or DLB. Exploratory post hoc analyses were also conducted to explore the lateral-specific effects of BF atrophy in relation to disease conversion.
methodsWe assessed 41 participants with polysomnography-confirmed iRBD and 38 healthy controls using baseline T1-weighted magnetic resonance imaging (MRI) and longitudinal clinical assessments. Gray matter volumes of the left and right BF were compared between groups. Cox proportional hazards models examined baseline BF volumes as predictors of phenoconversion risk to PD and DLB.
resultsAlthough no significant group differences in BF volume were found, lower BF volume was associated with poorer global cognition in iRBD. Bilateral BF atrophy predicted increased risk of phenoconversion to either PD or DLB. An exploratory post hoc analysis revealed that left BF atrophy specifically predicted conversion to DLB, whereas right BF volume did not.
conclusionBilateral BF atrophy may represent an early biomarker of phenoconversion in iRBD, with left-sided atrophy potentially indicating increased risk for DLB. These findings highlight the prognostic value of BF degeneration in prodromal synucleinopathies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.